Teledyne e2v Announces Next Generation High-performance CMOS Image Sensors for Extreme Low Light Conditions

GRENOBLE, France, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Teledyne e2v, a Teledyne Technologies company and global innovator of imaging solutions, announces OnyxMax™, the next generation of its popular Onyx 1.3M low light CMOS image sensor. This new sensor has been designed for extremely low light conditions, down to 1 mLux. The combination of sensitivity and image resolution increases its range, allowing even small objects to be detected in harsh conditions. This makes OnyxMax ideal for a wide range of applications including science, defense, traffic cameras, broadcast, surveillance, border control and astronomy.

OnyxMax features 1.3 Megapixels (1,280 x 1,024) and is available in monochrome, as standard, and with CFA arrangements available on request. It has a 10 x 10 µm pixel, designed with Teledyne’s new cutting edge HiRho™ proprietary technology, which enables outstanding Near Infrared (NIR) sensitivity and spatial resolution with Quantum Efficiency (QE) of 58% and MTF of 63% at 850nm wavelength. OnyxMax also provides an SNR of 10 dB at less than 2 mLux and at 60 frames per second and operates in rolling and global shutter modes, providing 75 dB of linear dynamic range. It also has a patented on-chip HDR mode which is capable of handling scene dynamics up to 100 dB.

Ariane Le Bon, Marketing Manager for Low Noise Imaging, at Teledyne e2v said, “We are very proud to release OnyxMax, which has been specifically designed to deliver high-performance in challenging low light conditions. This sensor performs significantly better than general purpose image sensors that generally lose contrast in the NIR. OnyxMax performs impressively in these conditions and has been very well received by defense, commercial, and scientific markets.”

See a live demo of OnyxMax at SPIE Photonics West, San Francisco, USA, 30 January – 1 February 2024. Visit us on Teledyne booth 327 or contact us online for more information.

Documentation and samples are available now upon request.

About Teledyne e2v

Teledyne e2v innovations lead developments in healthcare, life sciences, space, transportation, defense and security and industrial markets. Teledyne e2v’s unique approach involves listening to the market and application challenges of their customers and partnering with them to provide innovative standard, semi-custom or fully custom imaging solutions, bringing increased value to their systems.

For more information, visit imaging.teledyne-e2v.com.

Teledyne e2v media enquiries contact: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c856b1b7-1029-4b37-b450-35419a571a1a

Latest Press Release on Medical Gadgets

Gastro Concepts Receives FDA Clearance for Air Assist™ Device, Revolutionizing Colonoscopy Procedures

PR Newswire ALBUQUERQUE, N.M., Dec. 16, 2024 ALBUQUERQUE, N.M., Dec. 16, 2024 /PRNewswire/ -- Gastro Concepts, a team committed to advancing safety and efficiency in gastroenterology...

Tackling the ACL Tear Epidemic in Youth Athletes: A Promising Solution from Arthrex

PR Newswire NAPLES, Fla., Dec. 16, 2024 ACL reconstruction with Arthrex's InternalBrace™ technique proven to reduce retears by up to 80% in young athletes 1 NAPLES, Fla., Dec. 16...

Zimmer Biomet Receives FDA Clearance for OsseoFit™ Stemless Shoulder System for Total Shoulder Replacement

PR Newswire WARSAW, Ind., Dec. 13, 2024 New Anatomically Shaped Asymmetric Stemless Design for Total Shoulder Replacement WARSAW, Ind., Dec. 13, 2024 /PRNewswire/ -- Zimmer Biome...

Dynocardia has received a $1 million NSF grant to enhance their unique computer vision-based motion-correction technology and expand the applications of its ViTrack® continuous non-invasive blood pressure (cNIBP) monitor

PR Newswire CAMBRIDGE, Mass., Dec. 11, 2024 Dynocardia's proprietary computer-vision technology effectively identifies and compensates for movement artifacts. Overcoming these artifa...

Theradaptive Obtains FDA IDE Approval to Study OsteoAdapt™ SP in Additional Spinal Fusion Indications

PR Newswire FREDERICK, Md., Dec. 10, 2024 FREDERICK, Md., Dec. 10, 2024 /PRNewswire/ -- Theradaptive, a privately held, clinical stage biologics company developing protein therapeuti...